LifeMD's Third Reset: Trading 88% Gross Margins for a Pharmacy It Owns
Revenue and EBITDA guidance slashed, a revenue-recognition clean-up, and a quiet abandonment of the insurance story — wrapped around a genuinely better unit economic model
LFMD · Earnings Call · 2026-11-12
The Third Reset
Justin Schreiber did not ease into it. The first substantive sentence of his prepared remarks was the concession: “Last quarter, I told you we expected to exit the year at a $250 million revenue run rate. We won't. We now expect to exit at roughly a $200 million revenue run rate.” — Justin Schreiber, Chairman and Chief Executive Officer · 2026-11-12 Revenue came in at $44.6 million against a $48–51 million guide — down 7% year over year — and the full-year outlook was cut from $205.5–212.5 million to $188–191 million, with adjusted EBITDA swinging from roughly breakeven to negative $10.6–12.6 million. This is not the first time. In November 2025 the guide came down on RexMD customer acquisition costs. In August 2026 analysts were already asking about "the guidance cut." And in March of this year the CFO laid out a path to $25 million of annualized EBITDA exiting 2026 — a number that has now fully evaporated. Three resets in four quarters is no longer a bump; it is a pattern, and the market has priced it as one. The reasons given are three: branded GLP-1 fulfillment arrangements landed later in the quarter than modeled, marketing was deliberately cut by nearly a third sequentially, and early-2026 patient cohorts underperformed, prompting management to pause spend until repriced cohorts proved out.The Footnote That Matters More Than the Miss
The revenue miss is arithmetic. The disclosure buried in the CFO's prepared remarks is the more uncomfortable item:This is the second such clean-up in four quarters — in November 2025 there was a $1.1 million revision to prior periods with the same third-party pharmacy flavor. When a company is simultaneously asking investors to accept a radically different revenue-recognition basis, a revenue-recognition error in the immediately preceding two years is not a footnote. It is the whole credibility question, and it arrived alongside a 10-Q filed days later than the market expected.We identified some immaterial errors in how we recorded net revenues in certain arrangements with our third-party pharmacy providers. The errors primarily affected 2024 and 2025.
The Principal-Agent Switch: 88% to 57%
Here is the substantive strategic change. LifeMD now fulfills branded GLP-1s — Wegovy, Ozempic, Zepbound, Foundayo — directly through its own pharmacy under arrangements with Novo Nordisk and Eli Lilly. It buys inventory and acts as principal, so patient-pay amounts now hit the top line gross. The reported gross margin, which sat at 88.2% as recently as the last reported quarter, is going to fall a long way: “By the time we get to the end of 2027... I would not be surprised. I think investors should be expecting something that is going to be kind of in the mid- to low 60s and potentially even down into the high 50s. But that's not necessarily an indication of a diminishing economic return.” — Justin Schreiber, Chairman and Chief Executive Officer · 2026-11-12 He is directionally right, and the Street has seen this movie before — Hims management made the identical argument about branded versus compounded economics. The key detail is the CFO's admission that in the prior quarter LifeMD earned zero on branded dispenses, so every incremental fill is now pure gross profit: “this is all purely incremental EBITDA and gross profit margin for us on these products.” — Atul Kavthekar, Chief Financial Officer · 2026-11-12 The accounting optics get worse while the economics get better. That is a genuinely difficult thing to ask an $80 million market cap to underwrite, especially with working capital now required to float branded inventory — the reason for the new $12.5 million Avenue Capital term loan replacing the Citizens revolver.What Vanished: The Insurance Story
The most revealing thing in this transcript is something nobody said. For roughly five consecutive quarters, payer coverage was the central pillar of the LifeMD narrative — insurance access, Medicare Bridge, 100-plus plans, 220 million covered lives, a 33% customer acquisition cost reduction from turning insurance on. In March the CEO said flatly: “I think you're going to see the business move more and more towards commercial and government insurance patients over the coming quarters.” — Justin Schreiber, Chairman and Chief Executive Officer · 2026-03-09 Predating even that, the May call framed the whole transformation as a mix shift, not a retreat: “In 2025 we had heavy use of compounded GLP-1s. We have continued to migrate this business to where we think the future is-around branded drugs-and that is really the delta you are seeing.” — Atul Kavikar, Chief Financial Officer · 2026-05-06 Asked directly this quarter whether enterprise means selling into health plans and self-insured employers, the answer reversed the entire frame:The word health plan survives in this quarter's keyword set only as a low-conviction remnant. Medicare Bridge — which in May was described as something not even built into the model — now merits a single sentence about ongoing support. Meanwhile pricing change and marketing spend dominate: the introductory month cut from $75 to $39, multi-month plan selection up from ~25% to ~85%, acquisition cost down 40% from a June peak. That is a real, measurable improvement in cohort quality. But it is a consumer-subscription business again, not the payer-infrastructure business investors were sold.We plan to really lean into the self-pay world, Dave. So, not what Omada does, where you're integrated into a benefits plan.